Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Indivior to pay $30 million to settle health plans' Suboxone claims

Published 08/21/2023, 02:46 PM
Updated 08/21/2023, 04:56 PM
© Reuters. FILE PHOTO: Pharmacist Jim Pearce fills a Suboxone prescription at Boston Healthcare for the Homeless Program in Boston, Massachusetts January 14, 2013. REUTERS/Brian Snyder/File Photo
INDV
-

By Brendan Pierson

(Reuters) - Indivior has agreed to pay $30 million to settle a class action lawsuit filed in a U.S. court by health plans accusing the drugmaker of illegally suppressing generic competition for its opioid addiction treatment Suboxone.

The settlement, disclosed on Saturday in a filing by lawyers for the health plans in federal court in Philadelphia, must still be approved by a judge. Indivior is still facing claims by drug wholesalers that bought Suboxone from the Virginia-based company directly, with a trial scheduled in October.

"We remain focused on helping those suffering from substance use disorders and mental illness," Indivior CEO Mark Crossley said in a statement on Monday. "Resolving these legacy legal matters at the right value helps us further our mission for patients and creates greater certainty for our stakeholders."

Lawyers for the health plans did not immediately respond to requests for comment. They said in their filing that the deal was "fair, reasonable, adequate and in the best interests" of the class.

Suboxone was approved for U.S. sale in 2002. Indivior had the exclusive right to sell the treatment in tablet form until 2009.

The health plans and drug wholesalers claimed in their lawsuits that Indivior switched to an oral film version of Suboxone from a tablet version to extend its monopoly, just as generic manufacturers were poised to sell their own lower-cost tablets. Generic tablets obtained federal approval in 2013.

© Reuters. FILE PHOTO: Pharmacist Jim Pearce fills a Suboxone prescription at Boston Healthcare for the Homeless Program in Boston, Massachusetts January 14, 2013. REUTERS/Brian Snyder/File Photo

Indivior agreed in June to pay $102.5 million to settle related claims by 41 U.S. states and Washington, D.C. The company in 2020 agreed to pay $600 million to resolve U.S. government allegations that it fraudulently promoted Suboxone, including by marketing the film version as safer and less abuse-prone than similar drugs.

More than 80,000 people in the United States died in 2021 from overdoses involving opioids, according to the U.S. Centers for Disease Control and Prevention.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.